Healthcare Cost Reductions Associated with the Use of LAI Formulations of Antipsychotic Medications Versus Oral Among Patients with Schizophrenia

Author： Lin Jay

Publisher： Springer Publishing Company

ISSN： 1094-3412

Source： The Journal of Behavioral Health Services & Research, Vol.40, Iss.3, 2013-07, pp. : 355-366

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Use of Healthcare Services by Patients Treated with Risperidone Versus Conventional Antipsychotic Agents

By Gianfrancesco F.

PharmacoEconomics, Vol. 20, Iss. 6, 2002-06 ,pp. : 413-427

Adis International

Access to resources Recommend Favorite

Informed Consent and Antipsychotic Use in Patients with Schizophrenia: Issues and Recommendations

By Laugharne J.

CNS Drugs, Vol. 9, Iss. 1, 1998-01 ,pp. : 1-5

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox versus Infusional Deferoxamine in Transfusion-Dependent Thalassaemia Patients: US Healthcare System Perspective

By Delea Thomas E.

PharmacoEconomics, Vol. 25, Iss. 4, 2007-01 ,pp. : 329-342

Adis International

Access to resources Recommend Favorite

Antipsychotic Medications and the Elderly: Effects on Cognition and Implications for Use

By Byerly M.J.

Drugs & Aging, Vol. 18, Iss. 1, 2001-01 ,pp. : 45-61

Adis International

Access to resources Recommend Favorite

Cost-Utility Analysis of Treatment with Olanzapine Compared with Other Antipsychotic Treatments in Patients with Schizophrenia in the Pan-European SOHO Study

By Knapp Martin Windmeijer Frank

PharmacoEconomics, Vol. 26, Iss. 4, 2008-01 ,pp. : 341-358

Adis International

Access to resources Recommend Favorite